Increased hypothalamic microglial activation after viral-induced pneumococcal lung infection is associated with excess serum amyloid A production
- 387 Downloads
It is well established that lung pathology and inflammation are more severe during respiratory infections complicated by the presence of both bacteria and viruses. Whilst co-infection can result in invasive pneumococcal disease and systemic inflammation, the neuroinflammatory consequences of co-infection are poorly characterised.
In this study, we utilised a mouse co-infection model involving Streptococcus pneumoniae (S. pneumoniae) and influenza A virus (IAV) lung infection, and we also isolated microglia for ex vivo stimulation with pneumococcus or serum amyloid A (SAA).
Co-infection but not S. pneumoniae or IAV alone significantly increased the number of amoeboid-shaped microglia and expression of pro-inflammatory cytokines including tumour necrosis factor α (TNFα), interleukin-1β (IL-1β), interleukin-6 (IL-6), and C-C motif chemokine ligand-2 (CCL-2) in the hypothalamus. Pneumococcus was only detected in the hypothalamus of co-infected mice. In addition, the systemic inflammatory cytokines TNFα, IL-1β and IL-6 were not elevated in co-infected mice relative to IAV-infected mice, whereas SAA levels were markedly increased in co-infected mice (p < 0.05). SAA and its functional receptor termed formyl peptide receptor 2 (Fpr2) transcript expression were also increased in the hypothalamus. In mouse primary microglia, recombinant SAA but not S. pneumoniae stimulated TNFα, IL-1β, IL-6 and CCL-2 expression, and this response was completely blocked by the pro-resolving Fpr2 agonist aspirin-triggered resolvin D1 (AT-RvD1).
In summary, lung co-infection increased the number of ‘activated’ amoeboid-shaped microglia and inflammatory cytokine expression in the hypothalamus. Whilst persistent pneumococcal brain infection was observed, SAA proved to be a much more potent stimulus of microglia than pneumococci, and this response was potently suppressed by the anti-inflammatory AT-RvD1. Targeting Fpr2 with pro-resolving eicosanoids such as AT-RvD1 may restore microglial homeostasis during severe respiratory infections.
KeywordsMicroglia Neuroinflammation Pneumonia Serum amyloid A Resolvin-D1
Aspirin triggered-resolvin D1
C-C Motif Chemokine Ligand 2
Central nervous system
Formyl peptide receptor 2
Influenza A virus
Serum amyloid A
Tumour necrosis factor α
Pandemic influenza A viruses (IAV) cause significant lung pathology consequent to an excessive host immune response that is associated with poor clinical outcome . Clinically, many deaths attributable to pandemic IAV outbreaks have been associated with secondary bacterial complications driven by Streptococcus pneumoniae (S. pneumoniae) or the ‘pneumococcus’ which exacerbates the lung immunopathology . Acute IAV lung infections that predispose to secondary pneumococcal super-infections can also result in invasion of the bacterium into other organs including the brain . In addition to the pandemic super-infection setting, viral and bacterial co-infections occur frequently in susceptible people with underlying chronic lung disease such as COPD or asthma . The chronology of co-infection in susceptible COPD and severe asthma patients is different from super-infections, as the lower airways can be chronically infected with pathogenic bacteria before they encounter a viral pathogen. Acute flares or COPD ‘exacerbations’ associated with bacterial and viral co-infections are clinically more severe as they result in greater lung function impairment and longer hospitalisations . However, the central and neuroinflammatory consequences of bacterial and secondary acute viral co-infections have not been characterised.
In the classic pandemic super-infection setting, S. pneumoniae can enter the brain and proliferate in the central nervous system (CNS), and the ensuing inflammatory response can lead to brain injury and bacterial meningitis in severe cases . Whilst meningitis rarely occurs in susceptible individuals, severe respiratory infections do routinely cause prolonged sickness behaviour including fever, malaise, fatigue, poor sleep quality and social withdrawal. The onset of sickness behaviour is mediated by the production of soluble inflammatory cytokines such interleukin (IL)-1β, IL-6 and tumour necrosis factor alpha (TNFα) produced at the primary site of lung infection that enter the circulation . The production of peripheral cytokines can then act centrally to stimulate neuroinflammation through multiple pathways including activation of primary afferent nerves in the lung that project to the brain, activation of macrophage-like cells residing in the circumventricular organs and the choroid plexus brain regions characterised by highly permeable vasculature and overflow of systemic inflammation into the brain via cytokine transporters within the blood–brain barrier (BBB) (5). Peripheral administration of inflammatory cytokines induces symptoms of sickness including fever and activation of hypothalamic-pituitary-adrenal (HPA) axis. The paraventricular nucleus (PVN) of the hypothalamus is particularly active during infection, as this region indirectly stimulates adrenal glucocorticoid production. Whilst glucocorticoids can suppress peripheral cytokines production by blocking NFκB-mediated transcription, they can also promote central microglial activation and neuroinflammation .
Pro-inflammatory cytokines that enter the brain stimulate neuroinflammation by activating resident microglia [8, 9]. Systemic lipopolysaccharide (LPS) administration has been shown to markedly activate microglia, which then release pro-inflammatory cytokines, free radicals and proteases that can contribute to progressive neurodegeneration in the chronic setting [8, 9]. Peripheral production of inflammatory cytokines in response to viral and bacterial infection will also stimulate hepatic production of the acute phase protein serum amyloid a (SAA) . Circulating levels of SAA markedly rise during infection and decline with clinical recovery . We have previously shown that infectious exacerbations of chronic obstructive pulmonary disease (COPD) that are viral and bacterial in aetiology result in persistently elevated levels of circulating SAA . We have also previously shown that circulating levels of serum SAA are increased in co-infected mice relative to mice infected with either S. pneumoniae or IAV alone . SAA is a functional agonist for the Formyl peptide receptor 2 (Fpr2), which is expressed by multiple types of immune cells including neutrophils, monocytes, macrophages and microglia. This interaction promotes a pro-inflammatory state by simulating chemotaxis and expression of inflammatory cytokines [13, 14].
Fpr2 can also interact with an alternative class of lipid agonist known as resolvin-D1 (RvD1) and its stable aspirin-triggered epimer (AT-RvD1). AT-RvD1 allosterically modulates Fpr2 by actively opposing the actions of SAA to resolve lung inflammation and immunopathology [12, 13]. Whilst SAA is known to efficiently enter the brain from the circulation , its role in neuroinflammation in the context of respiratory co-infection is unexplored. In addition, as acute inflammation increases Fpr2 expression in primary microglia , pro-resolving mediators that target this receptor may represent an important target for modulating the function of microglia. To assess this, we have utilised our existing mouse co-infection model that exhibits excessive immunopathology in the lung . In this study, we report that the pneumococcal 19F serotype was cleared from the lungs by 7 days; however, in co-infected mice, S. pneumoniae persisted in the lung and was also found in the brain. We also report that co-infection caused persistent microglial activation in the hypothalamus and identify SAA as a potent inflammatory stimulus of microglia that can be blocked by AT-RvD1.
Male C57BL/6J mice (8–10 weeks old) from the Animal Resources Centre (Perth, Australia) were housed at 22 ± 1 °C under normal 12 h light/dark cycle and fed a standard chow and water ad libitum. All experiments were approved by the Animal Ethics Committee of RMIT University (AEC #1509) and performed in compliance with the National Health and Medical Research Council (NHMRC) of Australia guidelines. Mice were divided into four groups: SAL (saline), SP (S. pneumoniae), IAV and SPIAV (co-infected). On day 0 of the experiment, mice from the SP and SPIAV groups received S. pneumoniae (serotype 19F, strain EF3030, 105 CFU in 35 μL saline) intranasally under light isoflurane anaesthesia, whereas mice from the SAL and IAV groups received equivalent volume of saline. On day 1, mice from IAV and SPIAV groups received influenza A viruses (strain A/HKx31 (H3N2), 104 PFU in 30 μL saline) intranasally, whereas mice from the SAL and SP groups received equivalent volume of saline. On day 7, mice were culled by intraperitoneal overdose of sodium pentobarbitone, and blood was collected from the vena cava. Prior to tissue collection, mice were perfused free of blood via right ventricle with 10 mL ice-cold PBS. Tissues including nasopharynx, olfactory epithelium, olfactory bulbs, hypothalamus and lungs were excised and snap-frozen for further analysis.
Quantification of S. pneumoniae and influenza A virus
Quantitative real-time PCR (qPCR) was used to measure S. pneumoniae and IAV in target tissue. Briefly, bacterial DNA and viral RNA were isolated by homogenising tissue in Trizol (Life Technologies) using a TissueLyser (Qiagen) in accordance to the manufacturer’s instructions. S. pneumoniae DNA qPCR was performed using a commercial kit from Qiagen as per manufacturer’s instructions, and bacterial load was determined by using standard curve generated from a known quantity of pneumococci. RT-qPCR on polymerase A subunit (PA) gene of IAV was performed using TaqMan® Fast Virus 1-Step Master Mix as previously described . Viral load was determined by using standard curve generated from a known quantity of IAV.
Serum was separated from whole blood using Microvette® 500 Z-Gel tubes (Sarstedt AG&CO). Serum IL-6, IL-1β, TNFα and SAA levels were determined using commercial ELISA kits (Life Technologies) according to the manufacturer’s instructions.
Whole brains were dissected and fixed in 10% neutral buffered formalin. Brains were then processed, paraffin-embedded and sectioned coronally at a thickness of 5 μm. Sections were deparaffinised and antigens were retrieved by incubating sections in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) at 95 °C for 20 min. After blocking in 5% bovine serum albumin (BSA) supplemented with 20% horse serum (Life Technologies), sections were incubated in ionized calcium-binding adapter molecule 1 (Iba-1) antibody (rabbit anti-mouse Iba-1, Wako Pure Chemical Industries, 1: 200), Glial fibrillary acidic protein (GFAP) antibody (rabbit anti-mouse GFAP, DAKO, Agilent Technologies, 1: 200) or TNFα antibody (goat anti-mouse, R&D Systems, 1:50) for 2 h at room temperature. This was followed by 30 min incubation in secondary antibody (AlexaFluor 488 goat anti-rabbit IgG or Alexa 594 donkey anti-goat IgG, Life Technologies, 1:200) and 2 min incubation in DAPI (Life Technologies, 1:2000 from 5 mg/mL stock). Alternatively, sections were incubated with SAA antibody (goat anti-mouse SAA, R&D Systems, 1:200) for 2 h at room temperature, followed by 1-h incubation in secondary antibody (donkey anti-goat IgG biotinylated antibody, R&D Systems, 1:200) and 1-h incubation in avidin-biotin horseradish peroxidase (HRP) complex (VECTASTAIN® Elite® ABC-HRP Kit, Vector Laboratories Ltd). After development in diaminobenzidine (DAB) solution, sections were counter stained with haematoxylin.
Images were taken from hypothalamic paraventricular nucleus (PVN) containing sections (between − 0.70 and − 0.94 mm from the bregma) or hippocampus containing sections (3–4 sections per mouse for Iba-1 and GFAP staining; 1 section per mouse for SAA staining) using a VS120 Olympus slide scanner (Olympus) or a BX53 System Microscope (Olympus). Images were then analysed using Cellsens software (Olympus). Iba-1/GFAP immunoreactivity was determined by measuring the number of pixels above a set threshold value and expressed as a percentage of total pixels within the chosen region of interest. Density of microglia and astrocytes is expressed as an average of area faction of Iba-1and GFAP respectively. Number of activated microglia in PVN (amoeboid-shaped), identified morphologically with enlarged soma and fewer processes (< 4), was manually counted by two independent assessors who were blinded to group treatments. The values from each of the assessors were averaged to derive data presented in this study.
Microglia isolation and treatments
Naïve male C57BL/6J mice (8–10 weeks old) were perfused free of blood via right ventricle with 10 mL ice-cold PBS, and whole brains were collected. Cells were isolated from these brains using a Neural Tissue Dissociation Kit (Miltenyi Biotec) according to manufacturer instructions. Myelin was removed by centrifuging isolated cells in 37% Percoll solution (GE Healthcare Life Sciences). The cell pellets were re-suspended in culture medium (DMEM/F-12 supplemented with 10% fetal bovine serum and 100 U/mL Penicillin-Streptomycin, Life Technologies) and dispersed into 24-well plates. After 30 min incubation in 5% CO2 at 37 °C, cells in suspension were removed and enriched (> 90%) microglia were obtained by further washing off the non-adhering cells with culture medium as previously described . Microglia were then pre-treated with aspirin-triggered resolvin D1 (AT-RvD1, 10 nM, Cayman Chemical) or medium (Veh) for 40 min, followed by S. pneumoniae (MOI of 1), recombinant human Apo-SAA1 (SAA, 1 μM, PeproTech) or PBS (Veh) for 4 h. Medium was then removed. Cells were washed with PBS and collected for further analysis.
Reverse transcriptase quantitative PCR (RT-qPCR) for gene expression analysis
Total RNA was extracted and purified from tissue or primary microglia using RNeasy kit (Qiagen), from which cDNA was prepared using High Capacity cDNA Kit (Life Technologies) as previously described . qPCR was performed using bioinformatically validated Taqman primers/probes, namely TNFα, IL-1β, IL-6, CCL-2, Fpr2 and SAA1 (Life Technologies). The threshold cycle values (Ct) were normalized to a reference gene (glyceraldehyde phosphate dehydrogenase or GAPDH for isolated microglia and phosphoglycerate kinase 1 or PGK1 for brain tissue samples) and the relative fold change determined by the ΔΔCt value as previously described .
Data are presented as the mean ± SEM. All data were statistically analysed using GraphPad Prism 7.0 (Graphpad, San Diego, CA). Where detailed and appropriate, two-tailed Student’s unpaired t tests or one-way analyses of variance (ANOVA) with Bonferroni’s post hoc tests were used. p < 0.05 was considered to be statistically significant.
Hypothalamic neuroinflammation was only present in co-infected mice
Using the same tissue samples, pneumococcal levels were also determined by qPCR, where high pneumococcal carriage was detected in the nasopharynx of S. pneumoniae and co-infected mice, with no significant difference between these two groups (Fig. 1c). This strain of S. pneumoniae (EF3030) was effectively cleared from the lungs in the absence of IAV infection, with all the samples being at or below the limit of detection (Fig. 1d). In co-infected mice, pneumococcal lung load was significantly increased relative to S. pneumoniae infection alone, where 6/8 lung samples were above the limit of detection for this sensitive assay (Fig. 1d). These data are consistent with our previously published findings  that quantified pneumococcal load by viable count in the BAL fluid (BALF). In addition, blood and spleen samples were screened by RT-qPCR, and no detection of pneumococcus was observed (Fig. 1e, f).
Pneumococcal brain infection is elevated in co-infected mice
Hypothalamic SAA and Fpr2 transcript expression is elevated in co-infected mice
In addition to circulating SAA levels, SAA transcript in the hypothalamus showed a 50% increase in co-infected mice only (Fig. 5e). Furthermore, transcript levels of Fpr2, a receptor for SAA that regulates inflammatory and resolution signalling circuits, were significantly increased in co-infected mice (Fig. 5f). Immunohistochemistry staining for SAA in the PVN demonstrated little immunoreactivity in brain sections from saline-treated mice (Fig. 5g). Staining in co-infected brain sections identified intense vascular immunoreactivity that is consistent with elevated circulating SAA levels (Fig. 5h, arrows).
SAA induced inflammation in primary microglial cells that were blocked by AT-RvD1
In this study, we demonstrate that hypothalamic neuroinflammation was significantly increased as a consequence of pneumococcal and influenza A viral co-infection of the lower airways. The neuroinflammatory response was associated with an increase in the number of activated amoeboid microglia and inflammatory gene expression including IL-1β, IL-6, TNFα and CCL-2. The hypothalamus appeared to be particularly responsive to lung co-infection, as we did not observe any difference in microglial or astrocyte morphology in the hippocampus and whilst TNFα expression was increased, IL-6, IL-1β and CCL-2 expression were unaltered. This suggests that brain regions in close proximity to circumventricular organs that lack a contiguous BBB, such as the PVN, were exposed to a circulating factor that was increased in co-infected mice. Alternatively, pneumococcal entry into the hypothalamus may be driving this inflammatory response. We also show that pneumococcal brain entry occurs more frequently in the co-infection setting, and this appears to occur directly via the nasal cavity. Whilst hematogenous routes are known to facilitate pathogen entry into the CNS, there is evidence that the nasal cavity can provide an alternative route . The mouse-adapted pathogenic strains of IAV have been shown to enter the brain via olfactory nerves, and this stimulates a rapid cytokine and anti-viral response within the olfactory bulb . Our findings show that although low levels of IAV were detected in the hypothalamus, the immunological response to IAV was not present at day 7, likely due to the resolution process.
A secondary consequence of IAV infection was the persistent detection of S. pneumoniae in the hypothalamus of co-infected mice. S. pneumoniae can be readily detected in the CNS after bacteraemia ; however, the less invasive 19F serotype used in this study was not detected in the bloodstream or other organs. It is therefore plausible that the pneumococci in the hypothalamus were directly transported from the nasal cavity and IAV may have facilitated entry into the CNS via its neuraminidase activity [22, 23]. Since the detection of S. pneumoniae was quite low in the hypothalamus (1.6 CFU/mg tissue) and this serotype did not stimulate microglial activation under in vitro conditions at MOI of 1 CFU per cell, we investigated whether a specific component of the systemic inflammatory response was capable of contributing to neuroinflammation.
Notably, circulating SAA was significantly elevated in co-infected mice, in contrast to other inflammatory cytokines such as IL-1β, IL-6 and TNFα in the serum. Elevated serum SAA levels were also associated with intense SAA immunoreactivity in co-infected brain sections, which was localised to the vasculature within the hypothalamus. In the chronic setting, excessive SAA production is a precursor to secondary amyloidosis that can cause serious complications , and amyloid deposits can also accumulate within the brains of patients with systemic amyloidosis, particularly around circumventricular organs that lack a contiguous BBB . The acute SAA isoforms have been shown to readily cross the intact BBB, where radiolabelled SAA traversed the endothelial barrier to enter the brain parenchyma . In a recent study, a liver-specific SAA over-expressing transgenic mouse model was used to evaluate whether acute circulating SAA can contribute to neurodegenerative disorders . Excessive production of SAA in this transgenic model resulted in accumulation of SAA in the brain, and this stimulated an increase in microglial cell numbers and expression of pro-inflammatory cytokines including IL-6 and TNFα . In addition, chronic elevation of circulating SAA resulted in behavioural abnormalities that are indicative of depressive-like behaviour and social withdrawal . Importantly, our study provides a clinically relevant infectious model of excessive peripheral SAA production that leads to microglial pro-inflammatory activity and neuroinflammation.
The increase in circulating SAA and hypothalamic SAA transcript in our study was accompanied by increased expression of Fpr2 in the hypothalamus. Since a previous study demonstrated that SAA potently stimulates microglia relative to astrocytes , and as we did not see changes in astrocyte density in co-infected mice, we focused on defining how SAA mechanistically coordinates microglial activation. We specifically utilised the pro-resolving AT-RvD1, as Fpr2 is the only known receptor for this eicosanoid in mice and it is proven to be effective in various inflammatory disease models [13, 28, 29]. Using isolated microglia, we demonstrate that SAA potently stimulated expression of inflammatory cytokine genes. We also demonstrate for the first time that SAA-dependent microglial activation can be effectively blocked by AT-RvD1.
In summary, we show for the first time that high level of circulating SAA induced by viral and pneumococcal lung infection can lead to microglial activation and upregulation of proinflammatory cytokines in the hypothalamus in mouse brain. Our data suggests the pro-resolving actions of specialised lipid mediators that target Fpr2 such as AT-RvD1 should be considered as an alternative strategy to reduce this excessive and persistent microglial activation and neuroinflammation during severe respiratory co-infections.
This work was supported by National Health and Medical Research Council of Australia (grant number APP1067547) and Australian Research Council (grant number FT130100654).
Availability of data and materials
All supporting data generated and analysed during this study are included in this article.
SB and HW conceived and conducted the study. HW, SB, MB, LS performed the experiments. SS, MC, RV assisted in data analysis and interpretation. SB and HW wrote the paper. All co-authors provided intellectual input and critical editing to the paper. All authors read and approved the final manuscript.
All experiments were approved by the Animal Ethics Committee of RMIT University (AEC #1509) and performed in compliance with the National Health and Medical Research Council (NHMRC) of Australia guidelines.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 11.Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, Karlsson AS, Silvestrini R, Smallwood D, Vlahos R, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:269–78.CrossRefPubMedGoogle Scholar
- 13.Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, Wark PA, Hutchinson A, Irving LB, Levy BD, Anderson GP. Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012;109:935–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Dando SJ, Mackay-Sim A, Norton R, Currie BJ, St John JA, Ekberg JA, Batzloff M, Ulett GC, Beacham IR. Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev. 2014;27:691–726.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Majde JA, Bohnet SG, Ellis GA, Churchill L, Leyva-Grado V, Wu M, Szentirmai E, Rehman A, Krueger JM. Detection of mouse-adapted human influenza virus in the olfactory bulbs of mice within hours after intranasal infection. J Neuro-Oncol. 2007;13:399–409.Google Scholar
- 27.Barbierato M, Borri M, Facci L, Zusso M, Skaper SD, Giusti P. Expression and differential responsiveness of central nervous system glial cell populations to the acute phase protein serum amyloid a. Sci Rep. 2017;7:12158.Google Scholar
- 28.Tsai YF, Yang SC, Hwang TL. Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2012-2015). Expert Opin Ther Pat. 2016;26:1–18.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.